Gemcitabine Combined With Endostar and Envafolimab in Elderly Patients With Locally Advanced Nasopharyngeal Carcinoma

Last updated: September 24, 2023
Sponsor: Zhejiang Cancer Hospital
Overall Status: Active - Recruiting

Phase

2

Condition

Nasopharyngeal Cancer

Carcinoma

Treatment

Endostar and Envafolimab

Clinical Study ID

NCT06055816
GEE study
  • Ages > 65
  • All Genders

Study Summary

Gemcitabine Combined With Endostar and Envafolimab in Elderly Patients With Locally Advanced Nasopharyngeal Carcinoma

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Aged ≥65 years with newly pathologically confirmed NPC
  • Karnofsky performance status ≥60
  • Clinical stage III-IVA (Union for International Cancer Control and American JointCommittee on Cancer staging system for NPC, 8th edition)
  • Adequate organ function

Exclusion

Exclusion Criteria:

  • Cancer history
  • Prior radiotherapy, cytotoxic chemotherapy, immunotherapy or target therapy
  • Life-expectance within 6 months

Study Design

Total Participants: 40
Treatment Group(s): 1
Primary Treatment: Endostar and Envafolimab
Phase: 2
Study Start date:
September 28, 2023
Estimated Completion Date:
June 30, 2028

Connect with a study center

  • Zhejiang Cancer Hospital

    Hangzhou, Zhejiang 325000
    China

    Active - Recruiting

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.